The Chan‑Zuckerberg Biohub announced it had absorbed the EvolutionaryScale team to build a large‑scale initiative combining frontier compute, experimental biology, and AI to accelerate disease prevention and cures. EvolutionaryScale researchers — including co‑founder Alex Rives — will lead integrated efforts across datasets, instruments and modeling, with the Biohub committing substantial GPU capacity through 2028. Mark Zuckerberg and Chan‑funded statements framed the move as a concentrated investment in the next generation of AI‑powered scientific discovery, with ambitions spanning experimental automation, imaging, and model development. The transaction signals deepening ties between big tech and life‑science research and could shift how foundational biological datasets and large models are developed and governed.